Director, Global Value, Health Economics and Outcomes Research

Jazz Pharmaceuticals

. Define and drive global and US payer evidence strategy for pipeline assets from Phase 2/3 through regulatory approval and launch .

Posted 11/5/2026full-timeRemote • United States, United KingdomLead💰 $212,000 - $318,000 per yearWebsite

Core Competencies

Role fit

Core Competencies

Use this summary to align your resume positioning with the role.

Expertise in Health Economics and Outcomes Research (HEOR) with a strong focus on evidence generation strategies for pipeline assets, including health economic modeling and market access. Proven ability to lead cross-functional teams and mentor junior scientists while driving US pre-launch deliverables and global launch readiness.

Highest-signal resume keywords

Health Economics ModelingUS HEOR Strategy LeadershipPayer Evidence GenerationClinical Trial Protocol IntegrationMarket Access Evidence Strategies

ATS Keywords

Tailor your resume

Applicant Tracking System Keywords

Tip: use these terms in your resume and cover letter to boost ATS matches.

Hard Skills

Health EconomicsOutcomes ResearchPharmacoeconomicsEconomic ModelingPhase 2/3 Trial DesignBudget Impact ModelsNatural History StudiesComparative Effectiveness AnalysesHealth Technology AssessmentReal-World Evidence Generation

Soft Skills

Exceptional Communication SkillsMentoringCollaboration

Tools & Technologies

AMCP PIE DossiersGlobal ITCs/NMAsDecision-Tree ModelsMicrosimulation ModelsMarkov State-Transition Models

Industry Keywords

Biopharmaceutical IndustryManaged CareMedicare AdvantageMedicaidHTA FrameworksNeurology AssetsRare DiseaseOrphan Drug

About the role

Key responsibilities & impact

Define and drive global and US payer evidence strategy for pipeline assets from Phase 2/3 through regulatory approval and launch
Lead global payer evidence generation while serving as the US HEOR lead
Develop US pre-launch HEOR deliverables, payer field enablement tools, and US market access evidence strategies
Translate target product profiles and access ambitions into evidence generation programs
Partner with Clinical Development, Biostatistics, and Clinical Operations to integrate payer, formulary, and HTA requirements into Phase 2/3 trial designs
Optimize trial protocols, comparators, inclusion/exclusion criteria, treatment lines, and endpoints
Integrate PROs, HRQoL, symptom burden scales, and HCRU instruments into pivotal trials
Design evidence strategies for rare disease assets using natural history data, biomarkers, and external or historical comparator cohorts
Lead health economic modeling strategies, including conceptual models, threshold analyses, CEAs, and BIMs
Direct design, development, and validation of adaptable global core economic models
Lead US AMCP PIE dossiers, burden-of-illness dossiers, and US budget impact models
Design payer-facing economic models, evidence slide decks, and population health tools
Support ICER evaluations, IRA planning, and CMS price negotiation readiness
Lead HEOR workstreams within Launch Readiness Teams and oversee global launch evidence assets
Co-develop EU/INT HTA strategies and analytical packages for JCA, NICE, G-BA, CADTH, and other bodies
Design and execute pre-launch real-world studies, chart reviews, registries, and burden-of-illness evaluations
Govern the Integrated Evidence Generation Plan and coordinate cross-functional evidence priorities
Develop scientific publication plans, manuscripts, and congress presentations
Mentor junior HEOR scientists, post-doctoral fellows, and matrix colleagues

Requirements

What you’ll need

Master’s degree (MSc, MS, MPH, PhD) in Health Economics, Outcomes Research, Pharmacoeconomics, or a closely related quantitative field
Minimum of 7–10 years of experience in HEOR, Global Value, or Health Economics within the biopharmaceutical industry or a top-tier HEOR consulting firm
Experience with neurology assets preferred
Direct experience leading HEOR strategy and deliverables for pipeline assets, including early Phase 2/3 clinical trial protocol integration, endpoint development, and global launch readiness
Experience managing regional trade offs on evidence needs as part of Phase 2/3 protocol development
Launch lead for at least 2 assets as US HEOR lead, or country level HTA lead
Proven track record serving as the US HEOR lead or driving US pre-launch HEOR deliverables
Preferred direct experience in rare disease, orphan drug, or highly specialized pipeline programs
Demonstrated hands-on experience designing, overseeing, or adapting health economic models
Demonstrated track record collaborating with regional HEOR teams
Deep expertise in health economic modeling, including Markov state-transition, partitioned survival, microsimulation, and decision-tree models
Familiarity with US managed care and market access, Medicare Advantage, Medicare Part D/B, Medicaid, PBMs, and global HTA frameworks
Experience with GVDs, AMCP PIE dossiers, global ITCs/NMAs, US budget impact models, natural history studies, registries, external control arms, and specialized HTA pathways
Exceptional written and verbal communication skills, with an established record of HEOR and clinical publications or HTA success

Benefits

Comp & perks

Discretionary annual cash bonus or incentive compensation
Discretionary equity grants
Medical insurance
Dental insurance
Vision insurance
401k retirement savings plan
Flexible paid vacation